 |
Eisai's breast cancer drug ‘extends lives’Eisai's experimental breast cancer drug eribulin added an average of two and a half months to the lives of patients dying of breast cancer, which is a big improvement in such seriously ill cancer patients, researchers said. The results of More… |
Wednesday 24 April 2024
